Literature DB >> 9288770

Methylation hot spots in the 5' flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene.

X C Qian1, T P Brent.   

Abstract

The mechanism whereby the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) is silenced in repair-deficient (Mer-) human tumor cells is unknown. The role of methylation of the 5' CpG island in MGMT gene suppression is controversial. Although we previously showed by restriction enzyme analysis that CpG methylation in this region was associated with gene suppression, methylation at such sites was generally incomplete, suggesting heterogeneity. To clarify this issue, we have unequivocally defined the methylation status of every CpG by genomic sequencing of individual cloned copies of bisulfite-modified DNA. The region from -249 to +259 at the transcription start site was virtually methylation free in HT29 cells (Mer+), whereas in BE or HeLa S3 cells (Mer-), this region was substantially methylated in every DNA copy, with "hot spots" from -249 to -103 and from +107 to +196. Up-regulation of MGMT in HeLa S3 cells induced by 5-azacytidine was accompanied by progressive demethylation and the appearance of totally unmethylated copies of DNA. We conclude that, in Mer- cells, the MGMT promoter contains specific CpG methylation hot spots that are tightly linked to and are potential markers of gene silencing.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9288770

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  61 in total

1.  Promoter hypermethylation of RASSF1A, MGMT, and HIC-1 genes in benign and malignant colorectal tumors.

Authors:  Hamdy E Abouzeid; Abdel Meguid Kassem; Abdel Hady Abdel Wahab; Hatem A El-mezayen; Hayaat Sharad; Shaimaa Abdel Rahman
Journal:  Tumour Biol       Date:  2011-01-28

2.  Loss of O6-methylguanine-DNA methyltransferase protein expression is a favorable prognostic marker in diffuse large B-cell lymphoma.

Authors:  Toshihito Ohno; Junji Hiraga; Haruhiko Ohashi; Chiho Sugisaki; Eika Li; Haruhiko Asano; Tastuya Ito; Hirokazu Nagai; Yoriko Yamashita; Naoyoshi Mori; Tomohiro Kinoshita; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

3.  Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.

Authors:  Jill A Maxwell; Stewart P Johnson; Roger E McLendon; David W Lister; Krystle S Horne; Ahmed Rasheed; Jennifer A Quinn; Francis Ali-Osman; Allan H Friedman; Paul L Modrich; Darell D Bigner; Henry S Friedman
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

4.  Confluence-induced alterations in CpG island methylation in cultured normal human fibroblasts.

Authors:  R O Pieper; K A Lester; C P Fanton
Journal:  Nucleic Acids Res       Date:  1999-08-01       Impact factor: 16.971

5.  Methylation-specific multiplex ligation-dependent probe amplification identifies promoter methylation events associated with survival in glioblastoma.

Authors:  K L Rankeillor; D A Cairns; C Loughrey; S C Short; P Chumas; A Ismail; A Chakrabarty; S E Lawler; P Roberts
Journal:  J Neurooncol       Date:  2014-02-20       Impact factor: 4.130

6.  Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas.

Authors:  J L Blanc; M Wager; J Guilhot; S Kusy; B Bataille; T Chantereau; F Lapierre; C J Larsen; L Karayan-Tapon
Journal:  J Neurooncol       Date:  2004-07       Impact factor: 4.130

7.  Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.

Authors:  Luca Morandi; Enrico Franceschi; Dario de Biase; Gianluca Marucci; Alicia Tosoni; Mario Ermani; Annalisa Pession; Giovanni Tallini; Alba Brandes
Journal:  BMC Cancer       Date:  2010-02-18       Impact factor: 4.430

8.  Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide.

Authors:  K A van Nifterik; J van den Berg; W F van der Meide; N Ameziane; L E Wedekind; R D M Steenbergen; S Leenstra; M V M Lafleur; B J Slotman; L J A Stalpers; P Sminia
Journal:  Br J Cancer       Date:  2010-06-01       Impact factor: 7.640

9.  Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation.

Authors:  Emanuela Taioli; Camille Ragin; Xiao-Hong Wang; Jiangying Chen; Scott M Langevin; Ashley R Brown; Susanne M Gollin; Seymour Garte; Robert W Sobol
Journal:  BMC Cancer       Date:  2009-10-06       Impact factor: 4.430

10.  MeCP2/H3meK9 are involved in IL-6 gene silencing in pancreatic adenocarcinoma cell lines.

Authors:  Mario Dandrea; Massimo Donadelli; Chiara Costanzo; Aldo Scarpa; Marta Palmieri
Journal:  Nucleic Acids Res       Date:  2009-09-10       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.